MedTrace Logo

Biomarker Study of Blood Samples From Patients With Non-Small Cell Lung Cancer Treated With Carboplatin and Paclitaxel With or Without Bevacizumab

NCT00898417 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2017-05-19

No results posted yet for this study

Summary

RATIONALE: Studying samples of blood in the laboratory from patients undergoing treatment for non-small cell lung cancer may help doctors predict how patients will respond to treatment.

PURPOSE: This laboratory study is looking at proteomic patterns in stored blood samples from patients undergoing treatment for non-small cell lung cancer.

Conditions

Interventions

BIOLOGICAL

bevacizumab

DRUG

carboplatin

DRUG

paclitaxel

GENETIC

proteomic profiling

OTHER

laboratory biomarker analysis

OTHER

matrix-assisted laser desorption/ionization time of flight mass spectrometry

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • ECOG-ACRIN Cancer Research Group

    lead NETWORK

Principal Investigators

  • David P. Carbone, MD, PhD · Vanderbilt-Ingram Cancer Center

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-14
Primary Completion
2008-04-14
Completion
2008-04-14

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00898417 on ClinicalTrials.gov